- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 715603, 10 pages
Altered mRNA Expression Related to the Apoptotic Effect of Three Xanthones on Human Melanoma SK-MEL-28 Cell Line
1Department of Medical Biotechnology, Flinders Medical Sciences and Technology, School of Medicine, Faculty of Health Science, Flinders University, Level 4, Health Science Building, Registry Road, Bedford Park, Adelaide, SA 5042, Australia
2Flinders Centre for Marine Bioproducts Development (FCMBD), Flinders University, Level 4, Health Science Building, Registry Road, Bedford Park, Adelaide, SA 5042, Australia
Received 30 April 2013; Revised 9 August 2013; Accepted 23 August 2013
Academic Editor: Heide Schatten
Copyright © 2013 Jing J. Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. Gupta and H. Mukhtar, “Chemoprevention of skin cancer through natural agents,” Skin Pharmacology and Applied Skin Physiology, vol. 14, no. 6, pp. 373–385, 2001.
- K. Nouri, Ed., Skin Cancer, McGraw-Hill Medical, New York, NY, USA, 2008.
- A. Orouji, S. Goerdt, and J. Utikal, “Systemic therapy of non-resectable metastatic melanoma,” Cancers, vol. 2, no. 2, pp. 955–969, 2010.
- Y. Akao, Y. Nakagawa, M. Iinuma, and Y. Nozawa, “Anti-cancer effects of xanthones from pericarps of mangosteen,” International Journal of Molecular Sciences, vol. 9, no. 3, pp. 355–370, 2008.
- H. A. Jung, B. N. Su, W. J. Keller, R. G. Mehta, and A. D. Kinghorn, “Antioxidant xanthones from the pericarp of Garcinia mangostana (Mangosteen),” Journal of Agricultural and Food Chemistry, vol. 54, no. 6, pp. 2077–2082, 2006.
- J. Pedraza-Chaverri, N. Cárdenas-Rodríguez, M. Orozco-Ibarra, and J. M. Pérez-Rojas, “Medicinal properties of mangosteen (Garcinia mangostana),” Food and Chemical Toxicology, vol. 46, no. 10, pp. 3227–3239, 2008.
- T. Shan, Q. Ma, K. Guo et al., “Xanthones from mangosteen extracts as natural chemopreventive agents: potential anticancer drugs,” Current Molecular Medicine, vol. 11, no. 8, pp. 666–677, 2011.
- J. J. Wang, Q. H. Shi, W. Zhang, and B. J. Sanderson, “Anti-skin cancer properties of phenolic-rich extract from the pericarp of mangosteen (Garcinia mangostana Linn.),” Food and Chemical Toxicology, vol. 50, no. 9, pp. 3004–3013, 2012.
- J. J. Wang, B. J. S. Sanderson, and W. Zhang, “Cytotoxic effect of xanthones from pericarp of the tropical fruit mangosteen (Garcinia mangostana Linn.) on human melanoma cells,” Food and Chemical Toxicology, vol. 49, no. 9, pp. 2385–2391, 2011.
- S. R. Datta, H. Dudek, T. Xu et al., “Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery,” Cell, vol. 91, no. 2, pp. 231–241, 1997.
- M. H. Cardone, N. Roy, H. R. Stennicke et al., “Regulation of cell death protease caspase-9 by phosphorylation,” Science, vol. 282, no. 5392, pp. 1318–1321, 1998.
- S. J. Gardai, D. A. Hildeman, S. K. Frankel et al., “Phosphorylation of Bax ser184 by Akt regulates its activity and apoptosis in neutrophils,” The Journal of Biological Chemistry, vol. 279, no. 20, pp. 21085–21095, 2004.
- B. D. Manning and L. C. Cantley, “AKT/PKB signaling: navigating downstream,” Cell, vol. 129, no. 7, pp. 1261–1274, 2007.
- J. B. Easton and P. J. Houghton, “mTOR and cancer therapy,” Oncogene, vol. 25, no. 48, pp. 6436–6446, 2006.
- D. A. Guertin and D. M. Sabatini, “Defining the role of mTOR in cancer,” Cancer Cell, vol. 12, no. 1, pp. 9–22, 2007.
- R. Ravi and A. Bedi, “NF-κB in cancer—a friend turned foe,” Drug Resistance Updates, vol. 7, no. 1, pp. 53–67, 2004.
- K. H. Seo, H. M. Ko, H. A. Kim et al., “Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-κB activation,” Cancer Research, vol. 66, no. 9, pp. 4681–4686, 2006.
- A. Munshi, J. F. Kurland, T. Nishikawa, P. J. Chiao, M. Andreeff, and R. E. Meyn, “Inhibition of constitutively activated nuclear factor-κB radiosensitizers human cells,” Molecular Cancer Therapeutics, vol. 3, no. 8, pp. 985–992, 2004.
- M. F. Romano, R. Avellino, A. Petrella, R. Bisogni, S. Romano, and S. Venuta, “Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells,” European Journal of Cancer, vol. 40, no. 18, pp. 2829–2836, 2004.
- J. Eberle, B. M. Kurbanov, A. M. Hossini, U. Trefzer, and L. F. Fecker, “Overcoming apoptosis deficiency of melanoma-Hope for new therapeutic approaches,” Drug Resistance Updates, vol. 10, no. 6, pp. 218–234, 2007.
- S. K. Mantena, S. D. Sharma, and S. K. Katiyar, “Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP,” Carcinogenesis, vol. 27, no. 10, pp. 2018–2027, 2006.
- M. S. Soengas, P. Capodieci, D. Polsky et al., “Inactivation of the apoptosis effector Apaf-1 in malignant melanoma,” Nature, vol. 409, no. 6817, pp. 207–211, 2001.
- J. J. Johnson, S. M. Petiwala, D. N. Syed et al., “α-mangostin, a xanthone from mangosteen fruit, promotes cell cycle arrest in prostate cancer and decreases xenograft tumor growth,” Carcinogenesis, vol. 33, no. 2, pp. 413–419, 2012.
- M. Müller, E. S. Schleithoff, W. Stremmel, G. Melino, P. H. Krammer, and T. Schilling, “One, two, three-p53, p63, p73 and chemosensitivity,” Drug Resistance Updates, vol. 9, no. 6, pp. 288–306, 2006.
- Q. Yu, “Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy,” Drug Resistance Updates, vol. 9, no. 1-2, pp. 19–25, 2006.
- E. Selzer, H. Schlagbauer-Wadl, I. Okamoto, H. Pehamberger, R. Pötter, and B. Jansen, “Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines,” Melanoma Research, vol. 8, no. 3, pp. 197–203, 1998.
- A. M. Hossini, J. Eberle, L. F. Fecker, C. E. Orfanos, and C. C. Geilen, “Conditional expression of exogenous Bcl-XS triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts,” FEBS Letters, vol. 553, no. 3, pp. 250–256, 2003.
- K. G. Wolter, M. Verhaegen, Y. Fernández et al., “Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins,” Cell Death and Differentiation, vol. 14, no. 9, pp. 1605–1616, 2007.
- M. Raisova, M. Bektas, T. Wieder et al., “Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release,” FEBS Letters, vol. 473, no. 1, pp. 27–32, 2000.
- V. N. Ivanov, A. Bhoumik, and Z. Ronai, “Death receptors and melanoma resistance to apoptosis,” Oncogene, vol. 22, no. 20, pp. 3152–3161, 2003.
- S. Fulda and K. M. Debatin, “Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy,” Oncogene, vol. 25, no. 34, pp. 4798–4811, 2006.
- S. Elmore, “Apoptosis: a review of programmed cell death,” Toxicologic Pathology, vol. 35, no. 4, pp. 495–516, 2007.
- A. Ashkenazi and V. M. Dixit, “Death receptors: signaling and modulation,” Science, vol. 281, no. 5381, pp. 1305–1308, 1998.
- D. R. Green and G. P. Amarante-Mendes, “The point of no return: mitochondria, caspases, and the commitment to cell death,” Results and Problems in Cell Differentiation, vol. 24, pp. 45–61, 1998.
- A. Krajarng, Y. Nakamura, S. Suksamrarn, and R. Watanapokasin, “α-mangostin induces apoptosis in human chondrosarcoma cells through downregulation of ERK/JNK and Akt signaling pathway,” Journal of Agricultural and Food Chemistry, vol. 59, no. 10, pp. 5746–5754, 2011.
- K. Matsumoto, Y. Akao, H. Yi et al., “Preferential target is mitochondria in α-mangostin-induced apoptosis in human leukemia HL60 cells,” Bioorganic and Medicinal Chemistry, vol. 12, no. 22, pp. 5799–5806, 2004.
- K. Matsumoto, Y. Akao, K. Ohguchi et al., “Xanthones induce cell-cycle arrest and apoptosis in human colon cancer DLD-1 cells,” Bioorganic and Medicinal Chemistry, vol. 13, no. 21, pp. 6064–6069, 2005.
- H. Zou, W. J. Henzel, X. Liu, A. Lutschg, and X. Wang, “Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3,” Cell, vol. 90, no. 3, pp. 405–413, 1997.
- J. Rodriguez and Y. Lazebnik, “Caspase-9 and APAF-1 form an active holoenzyme,” Genes and Development, vol. 13, no. 24, pp. 3179–3184, 1999.
- D. Chandra, J. Liu, and D. G. Tang, “Early mitochondrial activation and cytochrome c up-regulation during apoptosis,” The Journal of Biological Chemistry, vol. 277, no. 52, pp. 50842–50854, 2002.
- J. M. Adams and S. Cory, “The Bcl-2 protein family: arbiters of cell survival,” Science, vol. 281, no. 5381, pp. 1322–1326, 1998.
- B. Antonsson and J. C. Martinou, “The Bcl-2 protein family,” Experimental Cell Research, vol. 256, no. 1, pp. 50–57, 2000.
- D. C. S. Huang and A. Strasser, “BH3-only proteins—essential initiators of apoptotic cell death,” Cell, vol. 103, no. 6, pp. 839–842, 2000.
- J. R. Testa and A. Bellacosa, “AKT plays a central role in tumorigenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 20, pp. 10983–10985, 2001.
- D. R. Alessi, M. Andjelkovic, B. Caudwell et al., “Mechanism of activation of protein kinase B by insulin and IGF-1,” The EMBO Journal, vol. 15, no. 23, pp. 6541–6551, 1996.
- M. A. Shibata, M. Iinuma, J. Morimoto et al., “α-mangostin extracted from the pericarp of the mangosteen (Garcinia mangostana Linn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutation,” BMC Medicine, vol. 9, article 69, 2011.
- A. R. Han, J. A. Kim, D. D. Lantvit et al., “Cytotoxic xanthone constituents of the stem bark of Garcinia mangostana (mangosteen),” Journal of Natural Products, vol. 72, no. 11, pp. 2028–2031, 2009.
- A. Gorden, I. Osman, W. Gai et al., “Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues,” Cancer Research, vol. 63, no. 14, pp. 3955–3957, 2003.
- H. Davies, G. R. Bignell, C. Cox et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002.
- R. Kumar, S. Angelini, K. Czene et al., “BRAF mutations in metastatic melanoma: a possible association with clinical outcome,” Clinical Cancer Research, vol. 9, no. 9, pp. 3362–3368, 2003.
- H. Yang, B. Higgins, K. Kolinsky et al., “RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models,” Cancer Research, vol. 70, no. 13, pp. 5518–5527, 2010.
- E. W. Joseph, C. A. Pratilas, P. I. Poulikakos et al., “The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 33, pp. 14903–14908, 2010.
- D. S. Hong, L. Vence, G. Falchook et al., “BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency,” Clinical Cancer Research, vol. 18, no. 8, pp. 2326–2335, 2012.
- Y. Nakagawa, M. Iinuma, T. Naoe, Y. Nozawa, and Y. Akao, “Characterized mechanism of α-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells,” Bioorganic and Medicinal Chemistry, vol. 15, no. 16, pp. 5620–5628, 2007.